CR20200088A - Compuestos espirocíclicos y sus métodos de preparación y uso - Google Patents
Compuestos espirocíclicos y sus métodos de preparación y usoInfo
- Publication number
- CR20200088A CR20200088A CR20200088A CR20200088A CR20200088A CR 20200088 A CR20200088 A CR 20200088A CR 20200088 A CR20200088 A CR 20200088A CR 20200088 A CR20200088 A CR 20200088A CR 20200088 A CR20200088 A CR 20200088A
- Authority
- CR
- Costa Rica
- Prior art keywords
- making
- methods
- same
- compounds
- spirocycle
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102100029814 Monoglyceride lipase Human genes 0.000 abstract 1
- 101710116393 Monoglyceride lipase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551714P | 2017-08-29 | 2017-08-29 | |
| PCT/US2018/048388 WO2019046330A1 (en) | 2017-08-29 | 2018-08-28 | SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200088A true CR20200088A (es) | 2020-04-08 |
Family
ID=65526036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200088A CR20200088A (es) | 2017-08-29 | 2018-08-28 | Compuestos espirocíclicos y sus métodos de preparación y uso |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11161856B2 (enExample) |
| EP (1) | EP3675848B1 (enExample) |
| JP (1) | JP7177825B2 (enExample) |
| KR (1) | KR20200046053A (enExample) |
| CN (1) | CN111032034B (enExample) |
| AU (1) | AU2018326497A1 (enExample) |
| BR (1) | BR112020003946A2 (enExample) |
| CA (1) | CA3072926A1 (enExample) |
| CL (1) | CL2020000463A1 (enExample) |
| CO (1) | CO2020001715A2 (enExample) |
| CR (1) | CR20200088A (enExample) |
| DO (1) | DOP2020000040A (enExample) |
| EA (1) | EA202090296A1 (enExample) |
| EC (1) | ECSP20013332A (enExample) |
| ES (1) | ES2914363T3 (enExample) |
| IL (1) | IL272578A (enExample) |
| JO (1) | JOP20200022A1 (enExample) |
| MA (1) | MA50045A (enExample) |
| MX (1) | MX2020002254A (enExample) |
| PE (1) | PE20200665A1 (enExample) |
| PH (1) | PH12020500371A1 (enExample) |
| RU (1) | RU2020107039A (enExample) |
| SG (1) | SG11202000984YA (enExample) |
| WO (1) | WO2019046330A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| WO2017197192A1 (en) | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| WO2018053447A1 (en) | 2016-09-19 | 2018-03-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| CN112088001A (zh) | 2018-05-15 | 2020-12-15 | 隆德贝克拉荷亚研究中心有限公司 | Magl抑制剂 |
| CN111505410B (zh) * | 2020-04-02 | 2022-07-29 | 矽力杰半导体技术(杭州)有限公司 | 调光模式检测电路、方法和无调光检测电路及照明系统 |
| IL297470A (en) | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
| UY39516A (es) * | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| US20240174680A1 (en) | 2021-01-29 | 2024-05-30 | Cedilla Therapeutics, Inc. | Cdk2 inhibitors and methods of using the same |
| US12053459B2 (en) | 2021-06-26 | 2024-08-06 | Cedilla Therapeutics, Inc. | CDK2 inhibitors and methods of using the same |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US12378219B2 (en) * | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03008109A (es) | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| CA2665804A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| CA2716863A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| DK3093291T3 (da) | 2009-10-23 | 2019-07-29 | Janssen Pharmaceutica Nv | Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer |
| WO2011109277A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| RS59512B1 (sr) | 2012-09-25 | 2019-12-31 | Hoffmann La Roche | Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| US9771341B2 (en) * | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| CN108601769B (zh) * | 2015-11-20 | 2021-09-03 | H.隆德贝克有限公司 | 吡唑化合物及其制备和使用方法 |
| WO2017197192A1 (en) | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
-
2018
- 2018-08-28 US US16/642,713 patent/US11161856B2/en active Active
- 2018-08-28 JO JOP/2020/0022A patent/JOP20200022A1/ar unknown
- 2018-08-28 CR CR20200088A patent/CR20200088A/es unknown
- 2018-08-28 CA CA3072926A patent/CA3072926A1/en not_active Abandoned
- 2018-08-28 BR BR112020003946-2A patent/BR112020003946A2/pt not_active Application Discontinuation
- 2018-08-28 AU AU2018326497A patent/AU2018326497A1/en not_active Abandoned
- 2018-08-28 WO PCT/US2018/048388 patent/WO2019046330A1/en not_active Ceased
- 2018-08-28 EP EP18852217.1A patent/EP3675848B1/en active Active
- 2018-08-28 EA EA202090296A patent/EA202090296A1/ru unknown
- 2018-08-28 MA MA050045A patent/MA50045A/fr unknown
- 2018-08-28 SG SG11202000984YA patent/SG11202000984YA/en unknown
- 2018-08-28 MX MX2020002254A patent/MX2020002254A/es unknown
- 2018-08-28 KR KR1020207007712A patent/KR20200046053A/ko not_active Withdrawn
- 2018-08-28 RU RU2020107039A patent/RU2020107039A/ru unknown
- 2018-08-28 JP JP2020512612A patent/JP7177825B2/ja active Active
- 2018-08-28 PE PE2020000297A patent/PE20200665A1/es unknown
- 2018-08-28 ES ES18852217T patent/ES2914363T3/es active Active
- 2018-08-28 CN CN201880054296.1A patent/CN111032034B/zh active Active
-
2020
- 2020-02-10 IL IL272578A patent/IL272578A/en unknown
- 2020-02-14 CO CONC2020/0001715A patent/CO2020001715A2/es unknown
- 2020-02-21 DO DO2020000040A patent/DOP2020000040A/es unknown
- 2020-02-21 EC ECSENADI202013332A patent/ECSP20013332A/es unknown
- 2020-02-24 PH PH12020500371A patent/PH12020500371A1/en unknown
- 2020-02-25 CL CL2020000463A patent/CL2020000463A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3072926A1 (en) | 2019-03-07 |
| WO2019046330A1 (en) | 2019-03-07 |
| JOP20200022A1 (ar) | 2020-02-02 |
| DOP2020000040A (es) | 2020-08-31 |
| BR112020003946A2 (pt) | 2020-09-08 |
| ECSP20013332A (es) | 2020-04-22 |
| CL2020000463A1 (es) | 2020-07-10 |
| CN111032034B (zh) | 2023-05-02 |
| AU2018326497A1 (en) | 2020-02-20 |
| EP3675848A1 (en) | 2020-07-08 |
| US11161856B2 (en) | 2021-11-02 |
| KR20200046053A (ko) | 2020-05-06 |
| PH12020500371A1 (en) | 2020-12-07 |
| PE20200665A1 (es) | 2020-06-11 |
| JP2020532547A (ja) | 2020-11-12 |
| EP3675848A4 (en) | 2021-03-10 |
| CO2020001715A2 (es) | 2020-02-28 |
| RU2020107039A (ru) | 2021-09-30 |
| IL272578A (en) | 2020-03-31 |
| US20210214375A1 (en) | 2021-07-15 |
| MX2020002254A (es) | 2020-07-20 |
| SG11202000984YA (en) | 2020-03-30 |
| EA202090296A1 (ru) | 2020-08-03 |
| MA50045A (fr) | 2020-07-08 |
| CN111032034A (zh) | 2020-04-17 |
| JP7177825B2 (ja) | 2022-11-24 |
| EP3675848B1 (en) | 2022-03-23 |
| ES2914363T3 (es) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| PH12019501079A1 (en) | Magl inhibitors | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| PH12019501097A1 (en) | Magl inhibitors | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| PH12019501102A1 (en) | Magl inhibitors | |
| GB2541571A (en) | Pharmaceutical compositions | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| WO2015179559A3 (en) | Pyrazole compounds and methods of making and using same | |
| MX2017006694A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| EP4417262A3 (en) | Combination therapy | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MY178960A (en) | Hiv treatment formulation of atazanavir and cobicistat | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| MX2019014475A (es) | Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas. | |
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |